SUMMARYThe substantial discrepancy between the strong effects of functional foods and various drugs, especially traditional Chinese medicines (TCMs), and the poor bioavailability of these substances remains a perplexing problem. Understanding the gut microbiota, which acts as an effective bioreactor in the human intestinal tract, provides an opportunity for the redefinition of bioavailability. Here, we discuss four different pathways associated with the role of the gut microbiota in the transformation of parent compounds to beneficial or detrimental small molecules, which can enter the body's circulatory system and be available to target cells, tissues, and organs. We further describe and propose effective strategies for improving bioavailability and alleviating side effects with the help of the gut microbiota. This review also broadens our perspectives for the discovery of new medicinal components.

中文翻译：

---

基于肠道微生物群的生物利用度：新视角。

摘要功能食品与各种药物特别是中药的强效性存在显着差异，且其生物利用度差仍然是一个令人困惑的问题。了解肠道微生物群是人类肠道中有效的生物反应器，为重新定义生物利用度提供了机会。在这里，我们讨论了与肠道微生物群在母体化合物转化为有益或有害小分子过程中的作用相关的四种不同途径，这些小分子可以进入人体循环系统并可用于靶细胞、组织和器官。我们进一步描述并提出了在肠道微生物群的帮助下提高生物利用度和减轻副作用的有效策略。这篇综述也拓宽了我们发现新药用成分的视角。